Key opinion leaders highlight the MS treatment landscape. Ryan Haumschild, PharmD, MS, MBA: Now that we’ve talked about the background of multiple sclerosis [MS] in detail, I think it’s important for ...

Neurologists have found in a recent study that common drugs to treat multiple sclerosis lead to modest health benefits but very high costs, according to a news release from Kirkland, Wash.-based ...

Multiple sclerosis (MS) treatment could be on the brink of a significant breakthrough thanks to innovative research by Immunic Therapeutics. Speaking to Fierce Pharma, CEO Daniel Vitt shares insights ...

New MS treatments target myelin repair, neuroprotection, and CNS-resident immune cells, offering hope for progressive forms of the disease. Bruton tyrosine kinase inhibitors (BTKis) like tolebrutinib ...

An international panel of experts has proposed a new way to classify multiple sclerosis (MS) that would ultimately change the way patients are diagnosed and treated. The goal is to eventually move ...

Multiple sclerosis (MS) is a chronic disease of the nervous system that can lead to muscle weakness, vision loss, and paralysis. It occurs when the immune system attacks the myelin sheath that ...

Pre-clinical studies using a small molecule drug have shown promise as a potential new treatment for multiple sclerosis (MS). CAMH-led pre-clinical studies using a small molecule drug have shown ...

"The observed differential effects of high-efficacy disease-modifying agents across sexes underscore the importance of sex-specific considerations in making treatment decisions to personalize care in ...

In MS, immune system cells mistakenly attack myelin. With stem cell treatment, doctors use chemotherapy to destroy these existing immune cells. Then, they introduce the new stem cells, which are not ...

Kessler Foundation research scientist John DeLuca, PhD, has published a significant clinical article in Journal of Neurology, shedding light on the elusive nature of fatigue in multiple sclerosis (MS) ...

Initiating treatment for multiple sclerosis (MS) within 6 months of the first symptoms is associated with a significantly lower risk for severe disability one decade later, a new study suggests.